VTX:NOVN - Novartis Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
CHF 78.38 +0.34 (+0.44 %)
(As of 05/25/2018 04:00 PM ET)
Previous CloseCHF 78.36
Today's RangeCHF 77.72 - CHF 78.50
52-Week RangeCHF 72.45 - CHF 88.30
Volume11.21 million shs
Average Volume5.98 million shs
Market Capitalization$206.54 billion
P/E RatioN/A
Dividend Yield3.57%
BetaN/A

About Novartis (VTX:NOVN)

Novartis logoNovan, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum. The company's clinical stage product candidates comprise SB208, a topical antifungal gel that is in Phase II proof-of-concept trial for the treatment of athlete's foot and fungal nail infections; and SB414, a topical cream, which is in Phase Ib trial for the treatment of inflammatory skin diseases, such as psoriasis and atopic dermatitis. It has a license agreement with Sato Pharmaceutical Co., Ltd. Novan, Inc. was founded in 2006 and is headquartered in Morrisville, North Carolina.

Receive NOVN News and Ratings via Email

Sign-up to receive the latest news and ratings for NOVN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolVTX:NOVN
CUSIPN/A
Phone+41-61-3241111

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins15.47%
Return on Equity11.16%
Return on Assets6.10%

Miscellaneous

EmployeesN/A
Outstanding Shares2,330,000,000

Novartis (VTX:NOVN) Frequently Asked Questions

What is Novartis' stock symbol?

Novartis trades on the VTX under the ticker symbol "NOVN."

What price target have analysts set for NOVN?

19 Wall Street analysts have issued 12 month price targets for Novartis' shares. Their forecasts range from CHF 75 to CHF 98. On average, they anticipate Novartis' share price to reach CHF 87.74 in the next twelve months. View Analyst Ratings for Novartis.

Who are some of Novartis' key competitors?

Who are Novartis' key executives?

Novartis' management team includes the folowing people:
  • Mr. Robert Alexander Ingram, Exec. Chairman (Age 76)
  • Mr. G. Kelly Martin, CEO & Director (Age 59)
  • Dr. Nathan Stasko Ph.D., Co-Founder, Pres, Chief Scientific Officer & Director (Age 38)
  • Mr. Jeff N. Hunter, CFO, Chief Bus. Officer, Exec. VP & Company Sec. (Age 61)
  • Mr. Andrew Novak, VP & Chief Accounting Officer

Has Novartis been receiving favorable news coverage?

Press coverage about NOVN stock has been trending positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Novartis earned a news sentiment score of 0.33 on Accern's scale. They also assigned media stories about the company an impact score of 46.95 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

What is Novartis' stock price today?

One share of NOVN stock can currently be purchased for approximately CHF 78.38.

How big of a company is Novartis?

Novartis has a market capitalization of $206.54 billion.

How can I contact Novartis?

Novartis' mailing address is Lichtstrasse 35, BASEL, 4056, Switzerland. The company can be reached via phone at +41-61-3241111.


MarketBeat Community Rating for Novartis (NOVN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  119 (Vote Outperform)
Underperform Votes:  133 (Vote Underperform)
Total Votes:  252
MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe NOVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NOVN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Novartis (VTX:NOVN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
19 Wall Street analysts have issued ratings and price targets for Novartis in the last 12 months. Their average twelve-month price target is CHF 87.74The high price target for NOVN is CHF 98 and the low price target for NOVN is CHF 75. There are currently 3 sell ratings, 7 hold ratings and 9 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.322.322.272.29
Ratings Breakdown: 3 Sell Rating(s)
7 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
7 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
7 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: CHF 87.74CHF 87.74CHF 88.40CHF 85.82

Novartis (VTX:NOVN) Consensus Price Target History

Price Target History for Novartis (VTX:NOVN)

Novartis (VTX:NOVN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
4/27/2018UBSSet Price TargetNeutralCHF 80View Rating Details
4/23/2018JPMorgan Chase & Co.Set Price TargetNeutralCHF 84View Rating Details
4/20/2018CfraSet Price TargetBuyCHF 88View Rating Details
4/20/2018Credit Suisse GroupSet Price TargetSellCHF 80View Rating Details
4/20/2018BarclaysSet Price TargetSellCHF 75View Rating Details
4/19/2018Sanford C. BernsteinSet Price TargetBuyCHF 90View Rating Details
4/16/2018Berenberg BankSet Price TargetNeutralCHF 90View Rating Details
4/13/2018Jefferies GroupSet Price TargetBuyCHF 98View Rating Details
4/11/2018HSBCSet Price TargetBuyCHF 84View Rating Details
4/9/2018Independent ResearchSet Price TargetNeutralCHF 83View Rating Details
4/9/2018Baader BankSet Price TargetBuyCHF 95View Rating Details
3/28/2018Oddo BhfSet Price TargetBuyCHF 88View Rating Details
3/28/2018Deutsche BankSet Price TargetNeutralCHF 89View Rating Details
3/14/2018Societe GeneraleSet Price TargetBuyCHF 95View Rating Details
3/2/2018Goldman Sachs GroupSet Price TargetNeutralCHF 90View Rating Details
2/9/2018Kepler Capital MarketsSet Price TargetBuyCHF 88View Rating Details
1/25/2018Morgan StanleySet Price TargetBuyCHF 92View Rating Details
1/25/2018S&P GlobalSet Price TargetNeutralCHF 91View Rating Details
12/6/2017Bank of AmericaSet Price TargetSellCHF 87View Rating Details
(Data available from 5/25/2016 forward)

Earnings

Dividends

Novartis (VTX:NOVN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Novartis (VTX NOVN) Insider Trading and Institutional Ownership History

Insider Trading History for Novartis (VTX:NOVN)

Novartis (VTX NOVN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Novartis (VTX NOVN) News Headlines

Source:
DateHeadline
Novartis biosimilar Zessly gets EU approvalNovartis biosimilar Zessly gets EU approval
www.marketwatch.com - May 24 at 10:13 AM
Novartis data at ASCO and EHA reinforce companys commitment to reimagining cancerNovartis data at ASCO and EHA reinforce company's commitment to reimagining cancer
globenewswire.com - May 17 at 4:04 PM
At the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive sustainable growthAt the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive sustainable growth
globenewswire.com - May 16 at 3:55 PM
Novartis top lawyer exits over Trump attorney deal mistakeNovartis top lawyer exits over Trump attorney deal 'mistake'
www.reuters.com - May 16 at 3:55 PM
Novartis top lawyer exits over payment to Trump lawyerNovartis top lawyer exits over payment to Trump lawyer
finance.yahoo.com - May 16 at 10:29 AM
Novartis (NOVN) Receives Consensus Recommendation of "Hold" from BrokeragesNovartis (NOVN) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - May 14 at 3:41 AM
Novartis paid Trump lawyer Michael Cohen $1.2 million for Obamacare work he couldnt doNovartis paid Trump lawyer Michael Cohen $1.2 million for Obamacare work he couldn't do
finance.yahoo.com - May 10 at 10:24 AM
Novartis paid Trump ‘fixer’ Michael Cohen $1.2 mln to consult on ‘certain U.S. healthcare policy matters’Novartis paid Trump ‘fixer’ Michael Cohen $1.2 mln to consult on ‘certain U.S. healthcare policy matters’
www.marketwatch.com - May 9 at 3:59 PM
Novartis calls $1.2 million deal with Trump lawyers firm a mistakeNovartis calls $1.2 million deal with Trump lawyer's firm a 'mistake'
www.reuters.com - May 9 at 3:59 PM
Japans Takeda clinches £45.3 billion Shire deal as pharma M&A rolls onJapan's Takeda clinches £45.3 billion Shire deal as pharma M&A rolls on
uk.finance.yahoo.com - May 8 at 9:57 AM
FDA approves Novartis treatment for thyroid cancerFDA approves Novartis treatment for thyroid cancer
www.marketwatch.com - May 7 at 9:55 AM
Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximabSandoz receives complete response letter from the US FDA for proposed biosimilar rituximab
globenewswire.com - May 3 at 9:55 AM
Pfizer tops earnings estimates, driven by sales of pneumonia vaccine PrevnarPfizer tops earnings estimates, driven by sales of pneumonia vaccine Prevnar
finance.yahoo.com - May 1 at 3:55 PM
Novartis (NOVN) Given a CHF 80 Price Target by UBS AnalystsNovartis (NOVN) Given a CHF 80 Price Target by UBS Analysts
www.americanbankingnews.com - April 27 at 12:44 PM
Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from homeNovartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home
globenewswire.com - April 25 at 10:22 AM
Novartis (NOVN) Given a CHF 84 Price Target by JPMorgan Chase AnalystsNovartis (NOVN) Given a CHF 84 Price Target by JPMorgan Chase Analysts
www.americanbankingnews.com - April 23 at 8:46 AM
Novartis (NOVN) Given a CHF 85 Price Target by  AnalystsNovartis (NOVN) Given a CHF 85 Price Target by Analysts
www.americanbankingnews.com - April 20 at 6:56 PM
Novartis (NOVN) PT Set at CHF 88 by CfraNovartis (NOVN) PT Set at CHF 88 by Cfra
www.americanbankingnews.com - April 20 at 11:54 AM
Novartis (NOVN) Given a CHF 80 Price Target at Credit Suisse GroupNovartis (NOVN) Given a CHF 80 Price Target at Credit Suisse Group
www.americanbankingnews.com - April 20 at 9:50 AM
Novartis (NOVN) Given a CHF 75 Price Target by Barclays AnalystsNovartis (NOVN) Given a CHF 75 Price Target by Barclays Analysts
www.americanbankingnews.com - April 20 at 7:02 AM
Novartis profit, sales rise, maintains outlookNovartis profit, sales rise, maintains outlook
www.marketwatch.com - April 19 at 10:10 AM
Novartis CEO feels heat on U.S. generics, Cosentyx dropNovartis CEO feels heat on U.S. generics, Cosentyx drop
finance.yahoo.com - April 19 at 10:10 AM
Novartis profit rises, lifted by heart drug salesNovartis profit rises, lifted by heart drug sales
www.marketwatch.com - April 19 at 10:10 AM
Novartis (NOVN) PT Set at CHF 80 by UBSNovartis (NOVN) PT Set at CHF 80 by UBS
www.americanbankingnews.com - April 19 at 9:52 AM
Novartis (NOVN) Given a CHF 90 Price Target by Sanford C. Bernstein AnalystsNovartis (NOVN) Given a CHF 90 Price Target by Sanford C. Bernstein Analysts
www.americanbankingnews.com - April 19 at 6:36 AM
Novartis AG (NOVN) Receives Average Recommendation of "Hold" from AnalystsNovartis AG (NOVN) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 19 at 3:40 AM
Novartis (NOVN) PT Set at CHF 82 by S&P GlobalNovartis (NOVN) PT Set at CHF 82 by S&P Global
www.americanbankingnews.com - April 17 at 8:07 PM
Novartis (NOVN) PT Set at CHF 76 by UBSNovartis (NOVN) PT Set at CHF 76 by UBS
www.americanbankingnews.com - April 17 at 7:34 PM
Novartis (NOVN) PT Set at CHF 94 by Sanford C. BernsteinNovartis (NOVN) PT Set at CHF 94 by Sanford C. Bernstein
www.americanbankingnews.com - April 17 at 5:54 PM
JPMorgan Chase Analysts Give Novartis (NOVN) a CHF 84 Price TargetJPMorgan Chase Analysts Give Novartis (NOVN) a CHF 84 Price Target
www.americanbankingnews.com - April 17 at 3:03 PM
Novartis (NOVN) PT Set at CHF 97 by Jefferies GroupNovartis (NOVN) PT Set at CHF 97 by Jefferies Group
www.americanbankingnews.com - April 16 at 10:54 PM
Berenberg Bank Analysts Give Novartis (NOVN) a CHF 90 Price TargetBerenberg Bank Analysts Give Novartis (NOVN) a CHF 90 Price Target
www.americanbankingnews.com - April 16 at 7:00 AM
Novartis (NOVN) Given a CHF 88 Price Target by Morgan Stanley AnalystsNovartis (NOVN) Given a CHF 88 Price Target by Morgan Stanley Analysts
www.americanbankingnews.com - April 15 at 11:10 PM
Jefferies Group Analysts Give Novartis (NOVN) a CHF 98 Price TargetJefferies Group Analysts Give Novartis (NOVN) a CHF 98 Price Target
www.americanbankingnews.com - April 13 at 9:39 AM
Novartis (NOVN) PT Set at CHF 80 by Goldman SachsNovartis (NOVN) PT Set at CHF 80 by Goldman Sachs
www.americanbankingnews.com - April 12 at 11:21 PM
Novartis (NOVN) PT Set at CHF 84 by HSBCNovartis (NOVN) PT Set at CHF 84 by HSBC
www.americanbankingnews.com - April 11 at 12:37 PM
Novartis (NOVN) Given a CHF 80 Price Target at BarclaysNovartis (NOVN) Given a CHF 80 Price Target at Barclays
www.americanbankingnews.com - April 11 at 7:56 AM
Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leaderNovartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader
globenewswire.com - April 10 at 10:33 AM
Cfra Analysts Give Novartis (NOVN) a CHF 91 Price TargetCfra Analysts Give Novartis (NOVN) a CHF 91 Price Target
www.americanbankingnews.com - April 9 at 10:28 AM
Novartis (NOVN) Given a CHF 80 Price Target at UBSNovartis (NOVN) Given a CHF 80 Price Target at UBS
www.americanbankingnews.com - April 9 at 8:25 AM
Novartis (NOVN) Given a CHF 83 Price Target by Independent Research AnalystsNovartis (NOVN) Given a CHF 83 Price Target by Independent Research Analysts
www.americanbankingnews.com - April 9 at 8:25 AM
Novartis (NOVN) Given a CHF 97 Price Target at Sanford C. BernsteinNovartis (NOVN) Given a CHF 97 Price Target at Sanford C. Bernstein
www.americanbankingnews.com - April 9 at 8:24 AM
Baader Bank Reiterates CHF 95 Price Target for Novartis (NOVN)Baader Bank Reiterates CHF 95 Price Target for Novartis (NOVN)
www.americanbankingnews.com - April 9 at 8:07 AM
Baader Bank Reiterates "CHF 90" Price Target for Novartis (NOVN)Baader Bank Reiterates "CHF 90" Price Target for Novartis (NOVN)
www.americanbankingnews.com - April 5 at 7:58 PM
Goldman Sachs Reiterates "CHF 81" Price Target for Novartis (NOVN)Goldman Sachs Reiterates "CHF 81" Price Target for Novartis (NOVN)
www.americanbankingnews.com - April 5 at 4:38 PM
Novartis (NOVN) PT Set at CHF 75 by JPMorgan ChaseNovartis (NOVN) PT Set at CHF 75 by JPMorgan Chase
www.americanbankingnews.com - April 5 at 2:41 PM
Barclays Reiterates "CHF 75" Price Target for Novartis (NOVN)Barclays Reiterates "CHF 75" Price Target for Novartis (NOVN)
www.americanbankingnews.com - April 5 at 2:29 PM
Novartis (NOVN) PT Set at CHF 95 by Societe GeneraleNovartis (NOVN) PT Set at CHF 95 by Societe Generale
www.americanbankingnews.com - April 5 at 2:25 PM
Sanford C. Bernstein Analysts Give Novartis (NOVN) a CHF 97 Price TargetSanford C. Bernstein Analysts Give Novartis (NOVN) a CHF 97 Price Target
www.americanbankingnews.com - April 4 at 10:26 PM
 Analysts Give Novartis (NOVN) a CHF 90 Price Target Analysts Give Novartis (NOVN) a CHF 90 Price Target
www.americanbankingnews.com - April 4 at 2:58 PM

SEC Filings

Novartis (VTX:NOVN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Novartis (VTX NOVN) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.